Abstract |
In this study, we hypothesized that the mice immunized with the glycosylphosphatidylinositol (GPI) anchored 6-kDa early-secreted antigenic target (ESAT-6) DNA vaccine (ESAT-6-gpi) and the tumour vaccine B16F10-ESAT-6-gpi/IL-21 might significantly enhance immune responses and antimelanoma efficacy. Our experimental results indicated that the anti-ESAT-6 antibody induced by the DNA vaccine ESAT-6-gpi bound ESAT-6 to the surface of tumour vaccine to activate a complement classical pathway and resulted in the B16F10 tumour cell lysis and apoptosis, which served as a potential trigger for breaking melanomatous immune tolerance to elicit an initiation of natural antimelanoma immunity. Our innovative approach of using the DNA vaccine ESAT-6-gpi priming and the tumour vaccine B16F10-ESAT-6-gpi/IL-21 boosting induced strong antimelanoma immunity that inhibited melanomatous growth. These findings highlighted the DNA vaccine ESAT-6-gpi as an immune enhancer to augment the immune efficacy of the tumour vaccine B16F10-ESAT -6-gpi/IL-21 against melanoma in a mouse model.
|
Authors | X He, J Wang, F Zhao, D Chen, J Chen, H Zhang, C Yang, Y Liu, J Dou |
Journal | Scandinavian journal of immunology
(Scand J Immunol)
Vol. 78
Issue 1
Pg. 69-78
(Jul 2013)
ISSN: 1365-3083 [Electronic] England |
PMID | 23679337
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2013 John Wiley & Sons Ltd. |
Chemical References |
- Antigens, Bacterial
- Bacterial Proteins
- Cancer Vaccines
- ESAT-6 protein, Mycobacterium tuberculosis
- Glycosylphosphatidylinositols
- Interleukins
- Vaccines, DNA
- plasmanylinositol glycan
- interleukin-21
|
Topics |
- Animals
- Antigens, Bacterial
(immunology)
- Bacterial Proteins
(immunology)
- Cancer Vaccines
(immunology)
- Cell Line, Tumor
- Glycosylphosphatidylinositols
(administration & dosage)
- Immunization
- Interleukins
(immunology)
- Melanoma, Experimental
(therapy)
- Mice
- Mice, Inbred C57BL
- Vaccines, DNA
(immunology)
|